Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥90 | ¥81 | ¥81 | ¥94 |
| - Cash | ¥28 | ¥33 | ¥34 | ¥32 |
| + Debt | ¥63 | ¥65 | ¥66 | ¥68 |
| Enterprise Value | ¥124 | ¥113 | ¥113 | ¥130 |
| Revenue | ¥7 | ¥8 | ¥7 | ¥7 |
| % Growth | -20.1% | 27.2% | -3% | – |
| Gross Profit | ¥4 | ¥7 | ¥5 | ¥5 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| EBITDA | -¥2 | ¥1 | -¥1 | -¥2 |
| % Margin | -26.7% | 9.3% | -12.4% | -23% |
| Net Income | -¥2 | -¥2 | -¥1 | -¥1 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS Diluted | -18.48 | -26.38 | -8.45 | -14.85 |
| % Growth | 29.9% | -212.2% | 43.1% | – |
| Operating Cash Flow | -¥3 | -¥0 | ¥1 | -¥11 |
| Capital Expenditures | -¥0 | -¥0 | -¥0 | -¥0 |
| Free Cash Flow | -¥3 | -¥0 | ¥1 | -¥11 |